EGFR+ Lung Cancer | Clinical

ABCP Regimen Shows OS Benefit in Secondline NSCLC With EGFR Sensitizing Mutations

March 15, 2022

In a subgroup analysis of patients with non-small cell lung cancer who have EGFR sensitizing mutations, the regimen of atezolizumab plus bevacizumab plus carboplatin, and paclitaxel, had a stonger survival benefit compared to other therapies.